Accuray announced today that it has received FDA clearance for its Radixact Treatment Delivery Platform for radiotherapy.

The hardware and software solutions that are part of the system, Treatment Planning System and iDMS Data Management System, allow for faster and more efficient delivery of treatment, and according to the announcement, will be able to treat a wider range of cancer patients — including those undergoing retreatment.

Radixact has a linear accelerator that can produce a dose rate of 1,000 monitor units (MU) to increase the imaging speed of the system, megavoltage computed tomography (MVCT) imaging, and helical treatment delivery so clinicians can apply the right amount of radiation dose to a target while sparing surrounding healthy tissue.
“The Radixact System gives the radiation therapy team expanded capabilities across the widest range of patient cases, from the routine to the most complex, with precision, speed and efficient workflows,” said Joshua H. Levine, president and CEO of Accuray, in a statement.

Additionally, to guide clinicians in adapting to changes in the tumor, including size shape and location of the tumor in the patient, the Precision Treatment Planning System has "smart" automated workflows and decision-making tools.

Clinicians from the University of Wisconsin-Madison were involved in the development of the Radixact system, and Jennifer Smilowitz, Ph.D., a clinical associate professor at the university and one of the developers, said the Radixact builds on the strengths of Accuray's TomoTherapy system.

“Expanded delivery capabilities enable treatment with image-guided, intensity-modulated radiation therapy [IG-IMRT, an extremely accurate form of radiation therapy] to an expanded range of patients. New database features make the ring gantry-based system even easier to operate and integrate within a radiation oncology department,” she said.

In April, Accuray had submitted pre-market notification to the FDA for the system. “Working with clinicians we will continue the development of clinically relevant, leading-edge technologies with the potential to truly change the radiation therapy treatment experience,” said Levine at that time.

The system will be commercially released sometime in July to September of this year.

Business Affairs Homepage